Welcome to our dedicated page for MiNK Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on MiNK Therapeutics stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company dedicated to developing cutting-edge therapies for treating cancer and other immune-mediated diseases. The company's core focus lies in pioneering allogeneic invariant natural killer T (iNKT) cell therapies, which are designed to be off-the-shelf solutions, making them readily available for patients in need.
MiNK's flagship program, agenT-797, is currently in a Phase 2 trial aimed at treating second-line gastroesophageal cancer. This trial, led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center, builds on promising results from earlier studies where agenT-797 demonstrated the ability to overcome resistance to immune checkpoint inhibitors. The trial is exploring the combination of agenT-797 with other advanced treatments, such as botensilimab and balstilimab, to improve outcomes for patients with challenging gastrointestinal cancers.
Another significant candidate in MiNK's pipeline is MiNK-215, an IL-15 armored FAP-targeting CAR iNKT cell therapy. This candidate has shown remarkable efficacy in preclinical models for colorectal cancer liver metastases, overcoming the immune barriers typically posed by liver metastases.
The company recently reported a strong year-end financial position with ongoing collaborations, including a research agreement with ImmunoScape. MiNK Therapeutics continues to advance its clinical programs while maintaining a focus on scalable and reproducible manufacturing processes for its iNKT cell therapies.
Founded and headquartered in New York, NY, MiNK Therapeutics remains committed to delivering innovative and effective treatments for life-threatening diseases. For more information, visit their website or follow them on social media at @MiNK_iNKT.
MiNK Therapeutics has unveiled clinical data on their allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797, in a severe ARDS case at the ATS Annual Meeting. The subject, a 26-year-old post-renal transplant immunocompromised individual who developed severe hypoxemic respiratory failure due to COVID-19, was treated with a single dose of agenT-797. Significant clinical improvements included reduced inflammatory cytokines and successful extubation by day 37. The patient was discharged by day 60 and resumed normal activities within six months. These findings align with Phase 1 trial data, supporting the potential of agenT-797 in treating severe respiratory conditions in immune-compromised patients.
MiNK Therapeutics (NASDAQ: INKT) reported its Q1 2024 results, highlighting significant progress in its invariant natural killer T (iNKT) cell therapy programs. Key developments include a $5.8 million private placement financing at a 25% premium, which will expedite the clinical entry of MiNK-215 for solid tumors. Clinical trials for agenT-797 in gastroesophageal cancers are ongoing, with initial results expected later in 2024. Preclinical data showcased MiNK-215's potential in treating MSS colorectal cancer liver metastases. Financially, MiNK ended the quarter with $5.8 million in cash, reduced net losses to $3.8 million (down from $5.7 million in Q1 2023), and decreased operating expenses.
MiNK Therapeutics, Inc. announced a $5.8 million private placement financing to advance the clinical trials of MiNK-215, their leading allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein in solid tumors. The financing includes a 25% premium, selling 4,640,000 shares of common stock at $1.25 per share. The funding will help accelerate the clinical development of MiNK-215, planned to enter the clinic in early 2025. Additionally, Katie Chudnovsky has been appointed as a Board Observer, bringing extensive experience in the medical research field.
MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its first quarter 2024 financial results on May 14, 2024. The company is focused on developing iNKT cell therapies for cancer and immune diseases. An executive conference call and webcast will follow to discuss the results and provide a corporate update.
FAQ
What is the current stock price of MiNK Therapeutics (INKT)?
What is the market cap of MiNK Therapeutics (INKT)?
What does MiNK Therapeutics specialize in?
What is agenT-797?
What are the recent achievements of MiNK Therapeutics?
Where is MiNK Therapeutics headquartered?
What partnerships has MiNK Therapeutics established?
What is MiNK-215?
How does MiNK Therapeutics deliver their therapies?
How can investors get more information about MiNK Therapeutics?
What is the primary focus of MiNK Therapeutics' current research?
How does agenT-797 work?
